Clinical Trial Update: Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating MAPK inhibition to enhance radioiodine uptake in radioiodine-refractory metastatic thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Snippet

Sponsor: University Hospital, Essen | Conditions: Metastatic Thyroid Cancer | Phase 2 | Status: UNKNOWN